Ginkgo Bioworks Teams Up with Deep Origin for Drug Safety Innovations
In an exciting development for the biomedical field, Ginkgo Bioworks has announced a strategic partnership with Deep Origin aimed at creating advanced tools that predict drug safety. This initiative will be part of a 4.5-year project supported by a significant investment from the Advanced Research Projects Agency for Health (ARPA-H). The focus of this collaboration is to develop a groundbreaking computational platform known as PREDICTS, which stands for Pharmacological Research and Evaluation through Digital Integration and Clinical Trial Simulation.
The Vision Behind PREDICTS
PREDICTS aims to revolutionize drug safety protocols through innovative technology. Leveraging Ginkgo Bioworks' Datapoints platform, the project will focus on generating high-quality, structured datasets that support the training of artificial intelligence models. This includes examining the effects of small molecule drugs and genetic changes across various cell and tissue types.
Collaboration Insights
Key figures from both organizations have expressed their enthusiasm about the partnership. Jesse Dill, Senior Director at Ginkgo Bioworks, shared his excitement regarding the opportunity to work closely with Deep Origin. He noted that the dedicated team possesses an ambitious vision that aligns well with Ginkgo's goals to explore cellular responses to different drug treatments.
Innovation in Multi-Omics Data Generation
George Pilitsis, another director at Ginkgo, expressed gratitude for the collaboration, emphasizing their shared mission to push the boundaries of multi-omics data generation. This involves creating advanced, purpose-built in vitro models that are complemented by state-of-the-art AI technologies.
Dr. Natalie Ma's Perspective
Dr. Natalie Ma, Head of Business Development at Deep Origin, highlighted the importance of Ginkgo's platforms in providing robust data generation capabilities. She stated that with these high-throughput in vitro platforms, the team can model a variety of cell types across different tissues and organs, effectively transforming therapeutic research.
A Commitment to Innovation
This partnership showcases Ginkgo's dedication to collaborating with interdisciplinary teams to foster innovation in drug development. The innovative approach being taken underscores Ginkgo's expertise in producing extensive datasets that help assess the developability of small molecules.
Future Opportunities
As Ginkgo Bioworks continues to develop its offerings, the possibilities for enhancing drug safety protocols resonate profoundly throughout the pharmaceutical industry. Their commitment to R&D and collaboration with Deep Origin sets a noteworthy precedent for future partnerships and advancements in drug safety research.
Frequently Asked Questions
What is the primary goal of the Ginkgo Bioworks and Deep Origin partnership?
The primary goal is to develop innovative tools that enhance drug safety using advanced computational methods and artificial intelligence.
What does PREDICTS stand for?
PREDICTS stands for Pharmacological Research and Evaluation through Digital Integration and Clinical Trial Simulation.
How will Ginkgo’s Datapoints platform contribute to the project?
The Datapoints platform will generate high-quality datasets that are essential for AI training, covering various drug and genetic perturbations.
Who are the notable leaders involved in the initiative?
Notable leaders include Jesse Dill and George Pilitsis from Ginkgo Bioworks and Dr. Natalie Ma from Deep Origin.
How does this partnership reflect Ginkgo's overarching mission?
This collaboration reflects Ginkgo's commitment to driving innovation in drug development through partnerships that leverage cutting-edge technology and interdisciplinary expertise.
